PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 10:16:57 By Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

16 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

08 Apr 2025 08:00:15 By Nasdaq GlobeNewswire

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

27 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

25 Mar 2025 08:00:32 By Nasdaq GlobeNewswire

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

18 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

13 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Leadership to Participate in March Conferences

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

07 Mar 2025 08:45:00 By Nasdaq GlobeNewswire

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

27 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

26 Feb 2025 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

24 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

20 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

03 Dec 2024 08:00:33 By Nasdaq GlobeNewswire

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

14 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

02 Oct 2024 08:00:00 By Nasdaq GlobeNewswire